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Aims: There is a trend for more flexibility in timing of evidence generation in relation
to marketing authorization, including the option to complete phase III trials after
authorization or not at all. This paper investigated the relation between phase II and
III clinical trial efficacy in oncology.
Methods: All oncology drugs approved by the European Medicines Agency
(2007–2016) were included. Phase II and phase III trials were matched based on indi-
cation and treatment and patient characteristics. Reported objective response rates
(ORR), median progression-free survival (PFS) and median overall survival (OS) were
analysed through weighted mixed-effects regression with previous treatment, treat-
ment regimen, blinding, randomization, marketing authorization type and cancer type
as covariates.
Results: A total of 81 phase II-III matches were identified including 252 trials. Mean
(standard deviation) weighted difference (phase III minus II) was −4.2% (17.4) for
ORR, 2.1 (6.7) months for PFS and −0.3 (5.1) months for OS, indicating very small
average differences between phases. Differences varied substantially between indi-
vidual indications: from −46.6% to 47.3% for ORR, from −5.3 to 35.9 months for
PFS and from −13.3 to 10.8 months for OS. All covariates except blinding were asso-
ciated with differences in effect sizes for at least 1 outcome.
Conclusions: The lack of marked average differences between phases may encourage
decision-makers to regard the quality of design and total body of evidence instead of
differentiating between phases of clinical development. The large variability empha-
sizes that replication of study findings remains essential to confirm efficacy of oncol-
ogy drugs and discern variables associated with demonstrated effects.
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1 | INTRODUCTION
In drug regulation, historically, the standard requirement for approval of
a marketing authorization (MA) was at least 2 confirmatory high-quality
phase III randomized controlled trials.1,2 More recently, an increased
flexibility towards these evidentiary standards has been exhibited by
regulators. Between 2005–2012, 37% of indications approved by the
Food and Drug Administration were based on a single pivotal trial.3 MA
based on a single pivotal trial was granted in 45% of the European Med-
icines Agency (EMA) approvals during 2012–2016.4 These percentages
are vastly different throughout therapeutic areas, with antineoplastic
and immunomodulatory agents at the very top with 74% of approvals
based on a single pivotal trial. Approval based on more limited evidence
is especially apparent in special marketing authorization schemes such
as accelerated approval in the USA and conditional MA in Europe, with
75% and 85% of MAs based on a single pivotal trial.4,5 Additionally, a
significant portion of drugs are approved based on uncontrolled trials or
phase II trials only.4-9
Even though the benefit/risk balance assessed by regulators may
be positive, a concern voiced by other stakeholders is that deciding
on appropriate use of drugs approved based on relatively more limited
data will be impossible, either because relevant clinical endpoints are
not available or because of the uncertainty considering the reported
effect sizes.10,12,13 This concern is illustrated by recent studies that
show that evidence for clinical effectiveness on survival or quality of
life is often delayed or even lacking years after approval of conditional
MA products.14,15 Health technology assessment bodies and other
stakeholders have repeatedly emphasized that determining the value
of drugs is extremely complicated if evidence is too limited to reliably
estimate long-term clinically relevant effects.10,12
Uncertainties in established effects may be exacerbated through
the presence of a gap between clinical trials' efficacy and effectiveness
in practice, which appears to be present for some therapeutic areas
but not for others.16-21 With increasing amounts of drugs being
approved before phase III data are available, it is vital to know whether
such a gap also exists between phases II and III. It is expected that in
general, phase III trials will only be available if phase II results are posi-
tive. Even if there is no true underlying difference in effects between
the phases, corrected for other factors, this selection would lead on
average to a smaller effect in phase III due to regression to the mean.
Indeed, previous research for phase II and phase III trials within
advanced solid malignancies found that of 43 phase III trials, 81% had
lower objective response rates (ORR) than their preceding phase II tri-
als for the new drug arm. The mean difference was 12.9%. No predic-
tors for this difference were found.22 The lack of explanatory factors
endorses regression to the mean as a relevant factor as this cannot be
predicted. So far, no studies have evaluated whether differences
between phase II and phase III trials also apply for survival.
The goal of this study is to investigate differences in estimated
effect sizes between phase II and phase III clinical trials for oncology
drugs. Outcome measures included are objective response rate,
median progression-free survival and median overall survival.
Additionally, several factors are explored for associations with efficacy
differences.
2 | METHODS
2.1 | Drug selection
We searched the publicly available EMA website to identify all the
new active substances approved, refused or withdrawn by the EMA
for the treatment of cancer (ATC codes L + V23) between 1 January
2007 and 31 December 2016. Drugs targeted at side effects of cancer
treatment and cancer pain, supportive treatments, generics and bio-
similars were excluded. For each product, all indications were
assessed separately. For each indication, all efficacy trials listed in the
EMA Committee for Medicinal Products for Human Use European
public assessment report were retrieved. Additionally, phase III studies
not included in the EMA evaluation (e.g. published afterwards) were
located through searches in PubMed following a strategy that
included the international nonproprietary name, approved indication
and the keywords clinical trial and phase III. Only indications with
both phase II and phase III clinical trials were selected for further anal-
ysis. Trials for indications with only phase II results were included only
for descriptive analysis, to assess whether such trials had different
characteristics from phase II trials within indications for which phase
III trials were available.
2.2 | Data collection
From the trials, quantitative data on objective response rate (ORR),
median progression-free survival (PFS) and/or median overall survival
What is already known about this subject
• Drugs are increasingly being evaluated based on a single
pivotal trial, sometimes with only phase II data.
• Objective response rates reported in phase II trials are
higher than in phase III trials in solid malignancies.
What this study adds
• There are no marked average differences in effect esti-
mates between phase II and phase III trials in oncology,
but differences are subject to large variations between
indications.
• Differences in efficacy estimates measured in trials are
associated with multiple covariates.
• Replication of oncology trials remains essential to confirm
efficacy of oncology drugs and discern variables associ-
ated with demonstrated effects.
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(OS) were collected. In trials with multiple arms, these efficacy out-
comes were extracted with respect to the group of patients receiving
the investigational drug for the indication of interest. If available, rela-
tive effect measures (e.g. hazard ratios) were also included if the com-
parator treatment was equal between phase II and III studies. If ORR
outcomes were reported for the number of assessable patients, these
results were recalculated according to the intent-to-treat principle.
Furthermore, the following other features were collected: number of
participants, randomization (yes/no), blinding (yes/no; including
single-, double- and triple-blinding in yes), treatment regimen (dosing,
regimen, combination treatments), previous treatment (yes/no), mar-
keting authorization type (standard or conditional), cancer type
(haematological or solid), and mean age of the patient population
(or median if mean was not reported).
2.3 | Data categorization and analysis
Each combination of phase II and III trials was reviewed, and compati-
bility was assessed based on an algorithm that defined whether the
drug regimen and target population were identical. Only the studies
involving identical patients (in terms of mean age [within 10%] and
disease severity) and using the same agents following the same treat-
ment schedule and administered with a dosing at least 85% identical
were deemed valid for comparison. This algorithm was based on pre-
vious research.22 When an outcome (ORR, PFS, OS) was reported
within 1 or more trials for 1 of the phases, but not for the other phase,
this set was excluded from the analysis for this outcome but could still
be included for any of the other 2 outcomes. If median survival (PFS
or OS) was not reached, these trials were excluded for this specific
outcome. The exclusion of studies in which median survival was not
reached may lead to exclusion of entire sets but also to biased (lower)
estimates when other studies within that phase for the same drug–
indication combination do report median survival. How often this
occurred was recorded.
A separate analysis was carried out for each of the 3 endpoints
as dependent variables within a linear mixed-effects model with
clinical development phase (II/III) as a fixed effect. Each trial
entered the model individually but was grouped according to its
matched drug–indication combination by including a random effect
for drug–indication combination. The outcomes in each phase were
weighted according to the trial size (number of patients in the
applicable arm) within each drug–indication phase II or phase III set
of trials. Subsequently, each drug–indication combination had an
equal weight in the analysis. Six covariates were tested for fixed
effects: randomization, blinding, being a combination treatment,
having received previous treatment, marketing authorization type,
and cancer type. Starting with a full model, covariates and their
interactions were estimated and tested. We assessed the homosce-
dasticity and normality of residuals graphically and through
Kolmogorov–Smirnov tests. Data analyses were performed in R
software version 3.5.2. using the package lme4 designed for (non)
linear mixed-effects models.
3 | RESULTS
3.1 | Inclusion of drug–indication combinations
In total, 81 phase II-phase III drug–indication combinations (called
sets) were identified for which the age of the patient population, dos-
ing regimen and disease-related characteristics were appraised as
identical between development phases. There were 136 phase II and
116 phase III trials available for these sets. Often, within a set, multi-
ple phase II studies corresponded with a single phase III study or vice
versa. Within 9 sets, median survival was reported for at least 1 trial
in each phase, but not for all trials. One trial did not reach median PFS
and 8 did not reach median OS. Figure 1 shows the flowchart for the
selection of phase II-phase III matching sets for the 3 outcomes ORR,
median PFS and median OS. Table 1 shows the characteristics of the
included indications and trials.
3.2 | Mean effect sizes in phase II and phase III
Mean (standard deviation [SD]) ORR, weighted for the size of the tri-
als, was 41.2% (23.0) for phase II and 37.0% (24.8) for phase III. For
median PFS, the weighted means (SD) were 8.2 (4.2) and 10.3 (8.6)
months for phase II and phase III respectively, whereas these were
14.7 (6.3) and 14.4 (6.7) months for median OS. Unweighted mean
(SD) ORR was 41.2% (22.9) for phase II and 37.1% (24.4) for phase III.
Unweighted median PFS and OS for phase II and phase III were 8.4
(4.6), 10.3 (8.5) for PFS and 14.8 (6.3) and 14.4 (6.7) for OS, indicating
almost no effect of weighting. Scatterplots of outcomes in phase II vs
phase III for all drug–indication combinations are provided in Figure 2.
3.3 | Mean differences between effect sizes in
phase II and phase III
Unadjusted mean differences in results between phases were small.
Mean (SD) weighted difference (phase III minus phase II) for ORR was
−4.2% (17.4), indicating a slightly higher weighted average objective
response rate in phase II trials. For median PFS, mean weighted differ-
ence was 2.1 (6.7) months, whereas the mean difference was even
smaller for median OS: −0.25 (5.1) months. Comparative effects were
available for only 8 drug–indication combinations (6 of them reporting
a hazard ratio for median PFS and 5 reporting a hazard ratio for
median OS), rendering it impossible to perform statistical analyses.
3.4 | Differences in effect sizes between phase II
and phase III in individual indications
The large standard deviation for mean differences indicates that the
differences between effect sizes in phase II and in phase III in individ-
ual indications varied substantially. For individual drug–indication sets
the ORR varied between phase II and phase III from −46.6% to
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47.3%. For PFS, this range was −5.3 to 35.9 months and for OS the
range was −13.3 to 10.8 months. Differences in effects between
phases in individual drug–indication sets can also be expressed as a
percentage of the size of the measured effect in phase II (e.g. an ORR
of 30% in phase III and 20% in phase II means a 50% higher ORR in
phase III relative to phase II). The mean of these percentages was
43.9% for ORR and 50.8% and 24.9% for median PFS and OS,
respectively.
3.5 | Factors associated with effect sizes
In the multivariable linear mixed effects model, there was no associa-
tion between phase and effect estimates for any of the efficacy mea-
sures (see Table 2). All 6 covariates except blinding were associated
with the effect size in at least 1 of the analyses of efficacy outcomes,
but only previous treatment had a clear association with all 3 efficacy
outcomes. Interaction effects were also evaluated. The only consis-
tent interaction found was between haematological indication and
phase for ORR and PFS (both P < .01). This interaction indicated that
the mean difference for haematological vs nonhaematological prod-
ucts was 22.4% in phase II and 33.5% in phase III for ORR and 1.4 and
7.5 months for median PFS. The interaction was not observed for
median OS.
3.6 | Drug–indication combinations with only
phase II trials
There were 14 drug–indication combinations that only had phase II
results, together including 25 trials. The mean ORR (n = 24) for these
trials was 47.1% (range 10.5–90.5%), the average median PFS (n = 18)
F IGURE 1 Flowchart for the inclusion of phase II-phase III matched sets and trials. EMA: European Medicines Agency; NME: new molecular
entity; ORR: objective response rate; PFS: progression-free survival; OS: overall survival
TABLE 1 Characteristics of included trials. ORR = objective response rate; PFS = progression-free survival; OS = overall survival;
CMA = conditional marketing authorization; SD = standard deviation
Indications
All ORR Median PFS Median OS
81 74 62 45
Haematological (%) 20 (25) 17 (23) 12 (19) 7 (16)
CMA (%) 22 (27) 20 (27) 16 (26) 8 (18)
Phase II Phase III Phase II Phase III Phase II Phase III Phase II Phase III
Trials 136 116 121 105 108 85 66 59
Randomized (%) 44 (32) 116 (100) 39 (32) 105 (100) 34 (31) 85 (100) 17 (26) 59 (100)
Blinded (%) 10 (7) 43 (37) 8 (7) 37 (35) 5 (5) 28 (33) 4 (6) 17 (29)
Combination (%) 54 (40) 53 (46) 48 (40) 49 (47) 41 (38) 35 (41) 19 (29) 18 (31)
Previous treatment (%) 93 (68) 78 (67) 82 (68) 70 (67) 76 (70) 59 (69) 45 (68) 40 (68)
Mean participants (SD) 85 (101) 319 (199) 86 (105) 314 (197) 88 (112) 319 (187) 88 (134) 335 (207)
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was 9.2 months (range 1.2–24.7) and the average median OS (n
= 9) was 21.9 months (range 3.0–45.8). The average difference in
measured ORR between trials for the drugs that had multiple
phase II trials (n = 8), was 14.1% (SD: 7.3%), unweighted and
uncorrected for covariates. These findings indicate that results
between phase II trials are similarly variable as results between
phase II and phase III trials.
4 | DISCUSSION
Our results show that there are no consistent differences in objective
response rate, median PFS or median OS between development
phases for oncology drugs, when trial results are available for both
phases. Although the mean difference in effect sizes between phases
was small, there were large variations in differences between phase II
and III through all individual drug–indication combinations, which was
only partly explained by covariates describing the type of drug and
design of the studies.
The associations of covariates with effect sizes were mostly as
could be expected. Larger effect sizes were noted in untreated
populations, combination regimens, haematological indications and
conditionally approved products. The higher effect sizes within condi-
tionally approved products somewhat mitigate the uncertainty associ-
ated with more preliminary evidence related to the benefit/risk
balance. For OS, not all these effects were significant and the effect
for haematological drugs reversed, which is probably explained by a
combination of the small sample size and the fact that correlation
between surrogate endpoints and OS is not consistent throughout
oncology indications.24 Based on this study, we cannot conclude or
dismiss an association between effect size and blinding or
randomization.
4.1 | Implications of the study findings
Historically, in evaluations of evidence by stakeholders such as
regulators, health technology assessment bodies and clinical
guideline developers, more emphasis is placed on randomized
controlled phase III trials rather than on phase II trials.1,2 However,
approvals based on only nonrandomized, uncontrolled phase II
trials are becoming more common.4-7 Whether the effects mea-
sured in such trials translate to clinically relevant effects in practice
remains unclear.
The lack of a mean difference between phases in our dataset indi-
cates that the lack of a phase III study in itself may not necessarily
mean that the effects from phase II are problematically biased. Our
results also showed that trials for drugs approved based on solely
phase II results showed on average greater effect sizes than phase II
trials for drugs for which phase III trials were available. This suggests
that phase III trials may not always be necessary if adequate phase II
trials demonstrate convincing effects. However, although mean differ-
ences were small, there were large variations in differences between
phases in the dataset. The gap between effect sizes in phase II and in
phase III can represent a big proportion of the measured effect size in
phase II. A similarly large difference was found between trials for
drugs with multiple phase II trials without a phase III trial. These simi-
larities indicate that a large effect size measured in a phase II trial is
no guarantee for an equally impressive effect in a replication phase II
trial or a phase III trial.
F IGURE 2 Scatterplots of phase II vs phase III results for objective response rate (ORR), median progression-free survival (PFS) and median
overall survival (OS). Line: Y = x
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Many factors are associated with positive development path-
ways such as the type and size of the effect measured, the number
of institutions included in phase II trials, trial characteristic, the
inclusion of biomarker-driven objectives, funding sources, and inter-
actions with regulators.25-33 Our study confirms that factors related
to the indication, the study population and the quality of the trial
can be associated with efficacy differences between studies,
irrespective of phase. More importantly, our study highlights that
significant unexplained variation remains despite included covariates.
Thus, when oncology approvals are based on a single trial, there is a
risk that the estimated efficacy may be greatly reduced or even
absent in practice. Such unpredictable variability in effect sizes
makes it very difficult for stakeholders to determine the appropriate
treatment line and reimbursement level. Replicating studies with
slightly modified population and trial characteristics can help to con-
firm efficacy and to discern variables associated with demonstrated
effects. This is at odds with the recent trend of increased flexibility
of regulators in accepting single phase II or single phase III trials for
marketing authorization.4 Our finding that multiple other variables
are associated with differences in effect sizes between trials sug-
gests that we could have introduced additional variables to the
regression model. For example, the inclusion of biomarker-driven
objectives has been shown to be associated with a higher probabil-
ity of achieving development milestones.33 Differences in effect
sizes due to the covariates we included had no interaction with the
differences between development phases except for having a
haematological indication. We expect that the inclusion of more
covariates would not lead to more interactions with phase but it
might have provided us with additional information regarding the
reasons for the big variations in effect sizes. Finding all covariates
that may be associated with differences in effect sizes in similar
populations was not an objective of this study. This emphasizes that
replication of trials remains essential. In conclusion, based on our
results, replication of oncology trials and subsequent consideration
of the quality of design and total body of available evidence should
be preferred above demanding phase III trials in all situations.
TABLE 2 Summarizing multivariable regression analyses for the objective response rate (ORR), median progression-free survival (PFS) and
median overall survival (OS). MA = marketing authorization. * P < .05
Reference Coef. 95% confidence interval
Objective response rate (%)
Intercept 37.8% 30.6% 44.9%
Phase III Phase II −5.0% −10.2% 0.2%
Randomization Nonrandomized 1.7% −4.4% 7.9%
Blinding No blinding 1.3% −4.5% 7.1%
Conditional marketing authorization* Standard MA 9.6% 0.8% 18.4%
Haematological indication* Solid tumours 27.7% 18.2% 37.1%
Previous treatment* No previous treatment −17.5% −23.0% −11.9%
Combination therapy* Monotherapy 10.7% 4.5% 17.0%
Median progression-free survival (mo)
Intercept 7.1 4.8 9.6
Phase III Phase II 1.3 −0.6 3.3
Randomization Nonrandomized 0.2 −2.0 2.2
Blinding* No blinding 2.7 0.5 4.8
Conditional marketing authorization* Standard MA 5.4 2.6 8.4
Haematological indication* Solid tumours 4.3 0.7 7.6
Previous treatment* No previous treatment −3.2 −5.1 −1.4
Combination therapy Monotherapy 2.1 0.0 4.1
Median overall survival (mo)
Intercept 16.5 13.2 19.5
Phase III Phase II −1.6 −3.7 0.7
Randomization Nonrandomized 1.7 −0.6 4.4
Blinding No blinding 0.2 −2.2 2.3
Conditional marketing authorization Standard MA 5.0 0.2 9.7
Haematological indication Solid tumours −4.0 −9.4 1.5
Previous treatment* No previous treatment −3.7 −6.2 −1.2
Combination therapy Monotherapy 0.2 −2.4 2.9
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4.2 | Previous research
As far as we know, no previous studies have quantitatively
assessed the efficacy gap between development phases for survival
outcomes. One previous study has highlighted the efficacy gap in
objective response rate between phase II and phase III studies for
solid malignancies, finding a 12.9% higher ORR reported in phase II
as opposed to phase III studies.22 Our results show a smaller
difference (8.5% when restricted to solid malignancies). Because
the matching mechanisms were comparable, this difference is
probably explained by their shorter inclusion period, their inclusion
of products that were never submitted to regulators and their lack
of correction for covariates such as previous treatment and treat-
ment regimen.
4.3 | Limitations
We applied a selection mechanism to phase II–phase III sets. This
was necessary to produce valid comparisons but also means that
we excluded many trials for which no match existed in the
corresponding phase. Additionally, it was impossible to match trials
based on all known patient characteristics (for example genetic
scores), which may explain some of the observed variation not
attributable to the included covariates. The risk of such effects
strengthens our suggestion that replication of clinical trials in
slightly different populations can provide increased confidence in
effect sizes. Although the variability between phase II trials for
drugs that only had phase II trials seemed similar to the variability
between phase II and phase III in our cohort, the higher effect sizes
for drugs that do not have phase III results suggests important dif-
ferences between the 2 types of drugs. Our conclusions should be
interpreted accordingly. Selection bias is also introduced through
the exclusion of trials for which median survival was not reached.
However, the effect on PFS results is minor, since it affects only
1 set. The effect on OS is harder to estimate, as median survival
not being reached can have multiple reasons, including a shorter
trial duration or increased efficacy. Overall, we find consistent
results throughout all 3 efficacy outcomes which strengthens our
confidence in the conclusions. Nonrandomized studies are never
blinded, which means that there may be confounding between the
2 covariates. However, we included both blinding as well as ran-
domization in the multivariable model to mitigate this issue. Regula-
tory evaluations are often based on comparative efficacy (to active
control or placebo). Thus, another approach could be to look at dif-
ferences in comparative effect sizes instead of differences in abso-
lute effect sizes between phase II and phase III. We have found
that it is very rare for phase II and phase III trials to include the
same comparator within the same matched population (only
8 drug–indication combinations in our dataset). This indicates that,
in reality, comparisons between results in phase II and results in
phase III must also be done on absolute rather than comparative
effects, which asserts our approach and conclusions.
4.4 | Conclusions
Overall, effect estimates in this dataset of trials measuring objective
response rate and median progression free and/or overall survival did
not show marked average differences between phase II and phase III
trials for oncology drugs. These results may encourage decision-
makers such as clinicians, regulators or health technology assessment
bodies to regard the quality of design and total body of evidence,
including patient population and trial characteristics, instead of differ-
entiating between phases of clinical development. The large variability
in effect size differences throughout individual indications emphasizes
that proper replication of study findings remains essential to confirm
efficacy of oncology drugs and discern variables associated with dem-
onstrated effects.
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